Cigarette smoking promotes body weight reduction in humans while paradoxically also promoting insulin resistance (IR) and hyperinsulinemia. However, the mechanisms behind these effects are unclear. Here we show that nicotine, a major constituent of cigarette smoke, selectively activates AMP-activated protein kinase a2 (AMPKa2) in adipocytes, which in turn phosphorylates MAP kinase phosphatase-1 (MKP1) at serine 334, initiating its proteasome-dependent degradation. The nicotine-dependent reduction of MKP1 induces the aberrant activation of both p38 mitogen-activated protein kinase and c-Jun N-terminal kinase, leading to increased phosphorylation of insulin receptor substrate 1 (IRS1) at serine 307. Phosphorylation of IRS1 leads to its degradation, protein kinase B inhibition, and the loss of insulin-mediated inhibition of lipolysis. Consequently, nicotine increases lipolysis, which results in body weight reduction, but this increase also elevates the levels of circulating free fatty acids and thus causes IR in insulin-sensitive tissues. These results establish AMPKa2 as an essential mediator of nicotine-induced whole-body IR in spite of reductions in adiposity.
Insulin resistance (IR) is a condition in which the body's cells become less sensitive to the effects of insulin, so that higher levels of insulin are required to maintain its physiological functions. IR is often associated with obesity and inactivity. In contrast, physical exercise and weight loss often lead to improved insulin sensitivity 1 . Nicotine, a major constituent of cigarette smoke, promotes hyperinsulinemia and IR-metabolic abnormalities that are typically associated with type 2 diabetes, cardiovascular disease, and various cancers in smokers 2 . Paradoxically, cigarette smokers or individuals undergoing nicotine replacement therapy often have IR 3 even though, as a group, they typically have a lower body mass index than individuals who never smoke or prior to their smoking-cessation therapy 4 . This relationship is emphasized by the observation that when smokers cease smoking, they undergo substantial weight gain [4] [5] [6] . Indeed, long-term nicotine replacement therapy (nicotine gum) is used as a method of weight control 3, 7 , but this therapy has been reported to induce IR and other metabolic disorders 3 . Highlighting this inverse relationship between IR and body weight in smokers is the fact that smoking cessation is linked both to improvements in insulin sensitivity and to notable weight gain. The mechanisms by which cigarette smoke or nicotine replacement therapy cause IR even in the presence of body weight reduction remain poorly understood.
The c-Jun N-terminal kinase (JNK) and the p38 protein kinases (p38) belong to the family of stress-activated protein kinases. JNK is activated by inflammatory cytokines, free fatty acids, cigarette smoke, and nicotine 8 . It suppresses insulin signaling through IRS1 phosphorylation at serine (Ser) 307 and subsequent protein kinase B (AKT) inhibition 9, 10 . JNK activity is abnormally elevated in obesity 11 , and genetic ablation of Jnk in mice results in decreased adiposity, improved insulin sensitivity, and enhanced insulin signaling 11 . Consistent with these findings, administration of a pharmacological Jnk inhibitor to leptin receptor-deficient db/db mice substantially improves their glucose levels 12 , further supporting the notion that JNK is a key player in the development and progression of IR. Moreover, Jnk has been found to enhance lipolysis 13 . Despite reports that nicotine activates the p38-JNK signaling pathway in lung cancer cells 14 , keratinocytes 15 , and smooth muscle cells 16 in vitro, there is currently no evidence supporting the in vivo activation of this pathway by nicotine or smoking. Thus, the molecular mechanisms by which nicotine activates the p38-JNK pathway and induces whole-body IR remain elusive.
AMP-activated protein kinase (AMPK) is a threonine/serine kinase that plays an important role in energy metabolism and is considered a cellular 'fuel gauge' and redox sensor 17, 18 . Evidence indicates that AMPK inhibition causes IR, whereas AMPK activation increases insulin sensitivity 17, 18 . In previous studies, we reported that nicotine activates AMPK in both differentiated adipocytes from the mouse cell line 3T3-L1 and vascular smooth muscle cells 19, 20 . Furthermore, nicotine-induced weight loss is associated with the inactivation of hypothalamic Ampk in mice 21 . The aim of the present study was to evaluate whether AMPK activation in adipocytes contributes to the effects of nicotine on the development of IR in the presence of weight loss. Here we report that nicotine selectively activates Ampkα2 in mouse adipocytes, resulting in aberrant lipolysis that leads to a reduction in adiposity but also whole-body IR.
RESULTS

Effects of nicotine on insulin resistance
To establish a causal relationship between nicotine, IR, and weight loss, we administered nicotine (1.5 mg kg −1 day −1 for 6 weeks) through osmotic mini-pumps subcutaneously implanted into 10week-old high-fat-diet-treated C57BL/6J wild-type (WT) mice (Supplementary Fig. 1a) . The average serum concentration of nicotine during the treatment was 68 ± 5 ng ml −1 ( Supplementary  Fig. 1b) , which is similar to the clinically relevant concentrations found in habitual cigarette smokers 22 or users of nicotine-containing chewing gum users 23 . As expected, nicotine infusion induced glucose intolerance and hyperinsulinemia ( Fig. 1a) . Insulin levels induced by glucose infusion were consistently and significantly higher in nicotine-treated mice than in vehicle-treated mice ( Fig. 1a) . Likewise, nicotine-treated mice exhibited significantly elevated concentrations of glucose in an insulin tolerance test (ITT) compared to vehicle-treated mice ( Fig. 1a) . Consistently, in hyperinsulinemic-euglycemic (H-E) clamp tests ( Fig. 1b and Supplementary Fig. 1c ), nicotine-treated mice exhibited impaired glucose infusion rates (GIR), increased hepatic glucose production (HGP), and decreased rates of glucose clearance (R d ) compared to vehicle-treated mice, indicating that nicotine impairs hepatic insulin action and induces whole-body IR.
We also examined the glucose metabolic index (R g ) in individual tissues during the H-E clamp tests. Nicotine treatment resulted in R g measurements from tibialis anterior and soleus muscles that were lower than those resulting from vehicle treatment ( Fig. 1b) , indicating that nicotine induced IR in skeletal muscles. Most strikingly, nicotine treatment corresponded to R g measurements in epididymal white adipose tissue (eWAT) that were 90% lower than those from vehicle treatment ( Fig. 1c) .
Nicotine decreases adiposity but promotes lipolysis in mice
Nicotine-treated mice had significantly lower body weight than vehicletreated mice (Fig. 1d) . MRI revealed that nicotine-treated mice also had significantly less WAT than vehicle-treated mice (Fig. 1e) . Furthermore, nicotine treatment resulted in less fat mass and smaller adipocyte size (49.3 versus 83.5 µm in diameter), but unchanged lean body mass, as compared to vehicle treatment ( Fig. 1e,f) . Nicotine did not change the temperature of the skin surrounding brown adipose tissue (BAT) or the rectal temperature in treated mice ( Fig. 1f ).
Next we investigated whether the smaller adipocytes observed in nicotine-treated mice were the result of enhanced lipolysis. Under fasting conditions, serum concentrations of free fatty acids (FFAs) were similar between vehicle-and nicotine-treated mice ( Fig. 1g) . Because insulin inhibits lipolysis 24 , we assessed the effects of nicotine Tibialis Soleus  0  0  20  20  90  40  60  80  100  120  0  0  20  20  40  40  60  60  80  80  100  100  120  120  140   Veh   2 npg on insulin-mediated inhibition of lipolysis. Upon insulin perfusion, we found significantly (P < 0.05) lower serum concentrations of FFAs in vehicle-treated compared to nicotine-treated mice (Fig. 1g) . In these mice, serum FFA concentration was negatively correlated with fat mass (Fig. 1g) . In vivo lipolysis assays demonstrated that nicotine treatment was associated with an attenuation of insulin-dependent inhibition of lipolysis ( Fig. 1h) . As the activation of phosphodiesterases (PDEs) is a prominent feature of insulin's anti-lipolytic effects, we next monitored the effects of nicotine on PDE activity. As expected, nicotine blocked insulin-induced PDE activation ( Supplementary  Fig. 1d ). Although nicotine treatment did not alter either basal or isoproterenol (ISO)-induced lipolysis in isolated adipocytes of mouse WAT ( Fig. 1i) , it was significantly associated with lower insulinmediated inhibition of ISO-induced lipolysis than was seen after vehicle treatment ( Fig. 1i) . Moreover, liver and serum triglyceride concentrations were markedly higher after nicotine treatment than after vehicle treatment ( Supplementary Fig. 1e ). Taken together, these results indicate that nicotine promotes lipolysis. Unlike in previous experiments using a high dose of nicotine 21, 25 , the clinically relevant concentration of nicotine used here did not alter O 2 consumption (VO 2 ), CO 2 elimination (VCO 2 ), energy expenditure (EE), physical activity, or food intake in mice, as compared to those seen in mice receiving vehicle treatment ( Supplementary Fig. 1f ). However, nicotine treatment was associated with slightly increased VO 2 in parallel with modestly decreased VCO 2 , which resulted in a markedly decreased respiratory quotient (RQ) ( Fig. 1j) , indicating that nicotine induces fatty acid oxidation in vivo.
Acipimox decreases nicotine-induced FFA release and IR Elevated levels of circulating FFAs are linked to IR 26, 27 . To investigate whether nicotine-induced lipolysis contributes to whole-body IR and weight loss, mice were simultaneously treated with nicotine and acipimox, a potent chemical inhibitor of lipolysis 28 (Supplementary  Fig. 2a ). Treatment with acipimox alone (0.08 g kg −1 day −1 ) for 5 weeks had no effects on the body weight, fat mass, lean mass, or serum insulin concentration of mice and did not alter results of intraperitoneal glucose tolerance tests (IPGTTs) or ITTs (data not shown). In addition, administration of acipimox did not alter the serum nicotine concentrations, EE, VO 2 , VCO 2 , physical activity, or food intake of nicotine-perfused mice, as compared to mice npg perfused with nicotine but not administered acipimox ( Supplementary  Fig. 2b,c) . However, administration of acipimox blunted nicotine's effects of lowering body weight ( Fig. 2a) , fat mass ( Fig. 2b) , and adipocyte size when administered alone ( Fig. 2c) . Furthermore, administration of acipimox to nicotine-treated mice prevented the nicotine-induced increase of serum FFAs ( Fig. 2d ) and hepatic and serum triglyceride levels ( Supplementary Fig. 2d ), as well as the decrease of RQ ( Fig. 2e) . Because mice co-treated with acipimox and nicotine did not exhibit altered FFA uptake and esterification in vivo compared to mice treated either with vehicle or with nicotine alone (Supplementary Fig. 2e ), these data suggest that nicotine-induced lipolysis is the key event linking decreased adiposity with increased fatty acid oxidation. We performed IPGTTs and found that acipimox partially reversed nicotine-induced glucose intolerance ( Fig. 2f) . Acipimox also attenuated the effects of nicotine on insulin levels under fasting conditions ( Fig. 2f) , insulin release triggered by glucose injections (Fig. 2f) , and IR ( Fig. 2g) . In an H-E clamp test (Fig. 2h,i and Supplementary  Fig. 2f ), acipimox significantly attenuated nicotine-induced IR and markedly improved the nicotine-dependent impairment of GIR of nicotine-treated mice ( Fig. 2h) . Furthermore, acipimox pronouncedly ablated the increase in HGP levels, the inhibition of clamp R d , and the reduction of R g in tibialis anterior and soleus muscles seen in nicotine-treated mice ( Fig. 2i) , indicating that inhibition of lipolysis by acipimox ablated nicotine-induced whole-body glucose intolerance and muscle and liver IR. In contrast, acipimox did not affect the lower R g measurements in eWAT of nicotine-treated mice compared to that of vehicle-treated mice ( Fig. 2i) , which is consistent with the fact that WAT is not a primary site for FFA oxidation.
Next we assayed the effects of nicotine on insulin signaling in WAT, skeletal muscle, and liver tissues from mice. Acipimox abolished the nicotine-induced reduction of Irs1 protein in skeletal muscle and liver ( Fig. 2j ) but not in WAT ( Fig. 2j) . We found that nicotine suppressed insulin-stimulated Akt phosphorylation at Ser473 (pAkt) in skeletal muscle, liver, and WAT (Fig. 2j) , and that, interestingly, acipimox attenuated the effects of nicotine on pAkt in skeletal muscle and liver, but not in WAT ( Fig. 2j) .
Adipose Ampka2 is required for nicotine-enhanced lipolysis AMPK is a key energy and redox sensor 29 that plays a pivotal role in lipid metabolism 30 and insulin signaling 31, 32 . Ampk activation by nicotine enhances lipolysis in 3T3-L1 differentiated adipocytes 19 , but the manner of AMPK regulation in lipolysis is controversial [33] [34] [35] [36] [37] . To establish a causative role of Ampk in nicotine-induced IR and enhanced lipolysis, Ampkα1-deficient (Prkaa1 −/− ) and Ampkα2deficient (Prkaa2 −/− ) mice were treated with nicotine or vehicle (Supplementary Fig. 3a) . Serum nicotine concentrations and food intake were similar in Prkaa1 −/− mice and Prkaa2 −/− mice treated with nicotine ( Supplementary Fig. 3b,c) . Compared to vehicle treatment, nicotine infusion significantly induced glucose intolerance, fasting insulin levels, glucose-induced insulin release, and insulin intolerance in Prkaa1 −/− mice, but not in Prkaa2 −/− mice ( Fig. 3a-c) . Furthermore, nicotine treatment was associated with significantly lower body weight and fat mass in Prkaa1 −/− but not Prkaa2 −/− mice, as compared to mice receiving the vehicle treatment ( Fig. 3d and Supplementary Fig. 3d ). In addition, deficiency of Ampkα2, but not Ampkα1, prevented nicotine-induced WAT loss ( Supplementary  Fig. 3d ), adipocyte size reduction ( Fig. 3e) , FFA elevation ( Fig. 3f) , and hepatic and serum triglyceride elevation in mice ( Supplementary Fig. 3e ).
In the WAT of mice, nicotine treatment was significantly associated with higher levels of phosphorylated Ampk (pAmpk) and acetyl-coA carboxylase (pAcc) (Fig. 4a) . ACC is a well-established AMPK substrate 30 . Interestingly, the levels of pAmpk after nicotine treatment were significantly greater in adipose tissues (11-fold than after vehicle treatment) ( Fig. 4a ) than in the hypothalamus (1.1-fold), liver (2.3-fold) or muscle (1.8-fold) ( Supplementary Fig. 3f ).
As nicotine treatment resulted in significantly less fat mass than that did vehicle treatment, it was important to determine whether selective Ampkα2 deletion in WAT could prevent nicotine-induced npg IR and lipolysis. Consistent with a previous report using rat adipocytes 34 , Ampkα1 was the major isoform (approximately 85%) of Ampkα, whereas Ampkα2 was the minor isoform (approximately 15%) in WAT (Fig. 4b) .
To determine the contribution of adipose Ampkα isoforms in nicotine-induced IR, we treated adipocytespecific (via an Adipoq-Cre delete strain) Ampkα-knockout mice (Prkaa1 ∆ad and Prkaa2 ∆ad ) and littermate control mice (Con) with nicotine or vehicle (Supplementary Fig. 4a ). The serum nicotine concentrations and food intake in the three groups receiving nicotine treatment were similar (Supplementary Fig. 4b,c) . We found that nicotine treatment resulted in significantly less body weight in both Con and Prkaa1 ∆ad mice compared to vehicle treatment, but did not affect Prkaa2 ∆ad mice (Fig. 4c) . Nicotine treatment also resulted in significantly (P < 0.05) less fat mass ( Supplementary  Fig. 4d ) and smaller adipocyte sizes ( Fig. 4d) in Con and Prkaa1 ∆ad mice than was seen after vehicle treatment, but it did not affect these parameters in Prkaa2 ∆ad mice ( Supplementary Fig. 4d and  Fig. 4d ). Furthermore, nicotine ablated the inhibitory effects of insulin on circulating FFAs (Fig. 4e) and in vivo lipolysis (Supplementary Fig. 5e ) in both Con and Prkaa1 ∆ad mice, but not in Prkaa2 ∆ad mice, indicating that adipose Ampkα2 is responsible for WAT reduction and the aberrant lipolysis.
Nicotine induces insulin resistance through adipose Ampka2
Treatment with nicotine dramatically impaired glucose tolerance ( Fig. 4f) , insulin sensitivity (Supplementary Fig. 4f) , and glucose infusion-stimulated insulin release ( Supplementary Fig. 4g ) in Con and Prkaa1 ∆ad mice but not in Prkaa2 ∆ad mice. Moreover, nicotine was associated with lower Irs1 protein levels in WAT from Con and Prkaa1 ∆ad mice but not in that from Prkaa2 ∆ad mice (Fig. 4g) . Consistent with this, nicotine attenuated insulinstimulated phosphorylation of Akt at Ser473 in WAT from Con and Prkaa1 ∆ad mice but not Prkaa2 ∆ad mice (Fig. 4g) . Moreover, compared to vehicle, nicotine induced a higher degree of Irs1 phosphorylation at Ser307 in an Ampkα2-dependent manner (Fig. 4g) .
Finally, nicotine decreased total Irs1 protein level without altering the Irs1 mRNA level in all groups, as determined by RT-PCR (data not shown).
In addition to the regulation of Irs1 at Ser307 by the Jnk-p38 signaling pathway, it also is well established that mTOR-and S6K1-mediated phosphorylation of IRS1 at Ser636 and Ser639, respectively, leads to its inactivation and turnover 10, 38, 39 . Thus, we assayed pS6K and p-mTOR with or without nicotine, and found that nicotine did not alter the levels of pS6K (phosphorylated at threonine (Thr) 389) or p-mTOR (Ser2448) (Supplementary Fig. 5a ). In line with this, nicotine did not alter the levels of phosphorylation of Irs1 at Ser636 or Ser639 (Supplementary Fig. 5a ). As nicotine also did not alter the phosphorylation levels of Irs1 at Ser789 (Supplementary Fig. 5a) , a phosphorylation site for Sik2 and Ampk 29, 40 , nicotine-enhanced phosphorylation of Irs1 at Ser307 (Fig. 4g) is unlikely to be due to direct Ampk phosphorylation of Irs1, as this would have been likely to affect the phosphorylation of Ser789 also. npg JNK is reported to suppress insulin signaling by causing phosphorylation of IRS1 at Ser307 and subsequent AKT inhibition 9, 10 . We tested the possibility that p38 or Jnk activation may mediate the phosphorylation and degradation of Irs1. We found that nicotine treatment resulted in markedly higher levels of p-p38 and pJnk in WAT from Con and Prkaa1 ∆ad mice, but not Prkaa2 ∆ad mice (Fig. 4g) . Moreover, selective JNK inhibition with Jnk-IN-8 or p38 inhibition with SB203580 attenuated the nicotine-dependent phosphorylation of Irs1-Ser307 and the subsequent reduction of Irs1 protein expression in mouse embryonic fibroblast (MEF)-derived adipocytes (Supplementary Fig. 5b) . Overall, these results indicate that adipose Ampkα2 is required for the nicotine-dependent upregulation of the p38-Jnk pathway, and thus the subsequent increase in pIrs1, Irs1 degradation and Akt inhibition.
Ampka2 alters the post-translational homeostasis of Mkp1 MAP kinase phosphatase-1 (MKP1, encoded by DUSP1) is a wellcharacterized phosphatase that specifically suppresses the p38-JNK pathway [41] [42] [43] . Therefore, we investigated the role of Mkp1 in the nicotine-induced aberrant phosphorylation of p38 and Jnk. Under baseline conditions, the expression of both Dusp1 mRNA and Mkp1 protein in WAT was similar in all three mice models (Con, Prkaa1 ∆ad and Prkaa2 ∆ad ; Fig. 5a ). However, nicotine treatment resulted in markedly lower Mkp1 protein levels in the WAT of Con and Prkaa1 ∆ad mice but had no effect in the WAT of Prkaa2 ∆ad mice (Fig. 5a) . Interestingly, nicotine treatment did not alter Dusp1 mRNA levels in WAT from either vehicle-or nicotine-treated mice (Fig. 5a ), suggesting that a post-translation modification is responsible for the nicotinedependent reduction in Mkp1 levels.
The stability of Mkp1 can be altered by phosphorylation, so we determined whether nicotine treatment resulted in increased Mkp1 phosphorylation at serine or threonine. We found that nicotine significantly induced Mkp1 serine phosphorylation in an Ampkα2dependent manner, but had no effect on threonine phosphorylation (Fig. 5a) . Nicotine enhanced Ampkα2 binding with Mkp1 in MEF-derived adipocytes (Fig. 5b) . Furthermore, nicotine treatment dose-and time-dependently activated Ampk in isolated adipocytes as early as 1 h ( Fig. 5c and Supplementary Fig. 5c ), induced Mkp1 serine phosphorylation within 2 h, and markedly lowered Mkp1 protein levels at 3 h following the treatment, as compared to the levels seen at the initial time point (Fig. 5c) . These data suggest that Ampk might directly phosphorylate Mkp1 at a serine residue.
To this end, we analyzed all sequences around serine residues in the MKP1 protein (Supplementary Fig. 5d ). Computer alignment with an optimal AMPK substrate motif yielded several potential AMPK phosphorylation sites in MKP1, including Ser131, Ser334, and Ser359 (Supplementary Fig. 5d,e) . To further establish the roles of these potential phosphorylation sites in nicotine-induced MKP1 degradation, we generated three site-directed mutant constructs of MKP1 (MKP1-S131A, -S334A, and -S359A). In HEK293 human embryonic kidney cells transfected with WT MKP1, stimulation with nicotine resulted in dramatically greater MKP1 serine phosphorylation than did vehicle treatment (Fig. 5d) . Nicotine-induced MKP1 serine phosphorylation was abolished only in cells transfected with MKP1- S334A, but not with MKP1-S131A or -S359A, implying that Ser334 is the target of AMPK-mediated phosphorylation. Next we performed an in vitro kinase assay with the peptides corresponding to residues 126-135, 329-338, and 354-363 of MKP1. The SAMS peptide, a canonical AMPK target sequence 29 , was included as a positive control.
We found that only the peptide comprising residues 329-338 of MKP1 was phosphorylated by AMPKα2 (Fig. 5e) . Furthermore, mutation of serine to alanine at Ser6 of SAMS and Ser334 of MKP1 peptide 329-338 abolished AMPKα2-mediated phosphorylation, confirming that AMPKα2 directly phosphorylates MKP1 at Ser334. We next determined whether AMPK-dependent MKP1 phosphorylation was required for the degradation of MKP1. To this end, we found that nicotine-treated HEK293 cells exhibited greater MKP1 polyubiquitination than vehicle-treated cells, but expression of MKP1-S334A did not result in appreciable ubiquitination of MKP1 in either treatment group (Fig. 5f) . Moreover, we found that nicotine-dependent Mkp1 degradation was time dependent (Fig. 5c) and that MG132, an inhibitor of the 26S proteasome, blocked this nicotine-induced MKP1 degradation (Fig. 5g) . Taken together, these results imply that nicotine acts via AMPKα2 to phosphorylate MKP1 at Ser334, instigating MKP1 ubiquitination and proteasome-mediated degradation.
In isolated white adipocytes, nicotine induced the nuclear translocation of Ampkα2, but not Ampkα1 (Fig. 5h) , which in turn mediated the degradation of nuclear protein Mkp1 and the activation of p38 (Fig. 5h,i) . In parallel, nicotine treatment dramatically increased the pMkp1-Ser334-dependent signal in WAT of Con and Prkaa1 ∆ad mice but not in that of Prkaa2 ∆ad mice in vivo (Fig. 5j) . Taken together, these results support the notion that nicotine-induced, nuclear-localized Ampkα2 phosphorylates Mkp1 at Ser334, which instigates Mkp1 degradation with consequent activation of the p38-Jnk pathway. npg To further establish the role of Mkp1 in nicotine-induced IR and lipolysis, adenoviruses encoding Mkp1 or green fluorescent protein (GFP, control) were overexpressed in MEF-derived adipocytes. Compared to GFP overexpression, adenoviral overexpression of Mkp1 ablated nicotine-induced p38 and Jnk phosphorylation, blocked nicotine-induced Irs1 reduction, and reversed insulin-induced Akt phosphorylation (Fig. 5i) . Moreover, overexpression of Mkp1, but not GFP, abolished nicotine-inhibited insulin suppression of lipolysis in MEF-derived adipocytes (Fig. 5i) . These results suggest that reduction of Mkp1 is a key step in nicotine-induced lipolysis and IR.
Mkp1 loss is required for nicotine-mediated IR and lipolysis
We next explored the in vivo relevance of the in vitro findings regarding Mkp1 regulation by nicotine. We found that Dusp1 −/− (Mkp1 knockout) mice had low body weight, low fat mass (Fig. 6a) , enhanced in vivo lipolysis (Fig. 6b) , and small WAT cell size ( Supplementary  Fig. 6a) , similar to those observed in nicotine-treated mice. In addition, Dusp1 −/− mice displayed a metabolic phenotype similar to that of nicotine-treated mice, including impaired glucose tolerance ( Fig. 6c) and IR ( Fig. 6d-f) . Also similar to nicotine-treated WT mice, Dusp1 −/− mice exhibited elevated p38 activation, increased Irs1 phosphorylation at Ser307, and decreased Irs1 protein levels (Fig. 6g) . Overall, these results imply that downregulation of Mkp1 and consequent activation of the p38-Jnk pathway may cause enhanced lipolysis, low adiposity, and IR.
To further investigate the role of Mkp1 in nicotine-induced IR in vivo, Dusp1 −/− and WT mice were treated with either vehicle or nicotine. In WT mice, nicotine treatment correlated with lower body weight ( Fig. 6a) and fat mass ( Fig. 6a ) and smaller WAT cell size (Supplementary Fig. 6a ) compared to vehicle treatment. The serum nicotine concentrations, food intake, and lean mass in WT and Dusp1 −/− mice treated with nicotine were comparable ( Supplementary Fig. 6b-d) . In contrast, in Dusp1 −/− mice, nicotine treatment did not alter body weight (Fig. 6a) , fat mass ( Fig. 6a) , lipolysis ( Fig. 6b) , WAT cell size (Supplementary Fig. 6a ) or glucose tolerance ( Fig. 6c-f and Supplementary Fig. 6g,h) compared to vehicle treatment. As expected, nicotine-treated WT was associated with higher FFA levels and greater lipolysis ( Fig. 6b and Supplementary  Fig. 6e,f) . Moreover, nicotine treatment did not alter p38 activation, Irs1 phosphorylation at Ser307, or Irs1 protein level compared to vehicle treatment in Dusp1 −/− mice (Fig. 6g) . Taken together, these results suggest that Mkp1 reduction is required for nicotine-mediated IR and lipolysis.
Nicotine receptor AchRa7 mediates nicotine-stimulated Ampk activation
Nicotinic acetylcholine receptor subunit α7 (AchRα7) is the major receptor for nicotine 44, 45 . To establish the role of AchRα7 in nicotine-enhanced Ampk activation, we knocked down AchRα7 expression in adipocytes using a AchRα7-specific lentivirus shRNA. We found that, in a time-dependent manner, nicotine was associated with higher levels of reactive oxygen species (ROS) and pAmpk and lower levels of Mkp1 in MEF-derived adipocytes compared to the initial time point, and that knockdown of AchRα7 abolished these effects (Supplementary Fig. 7a ).
Furthermore, we detected AchRα7 expression in isolated adipocytes, hepatocytes, beta cells, and myocytes from WT mice. We found that the highest amounts of AchRα7 were in the adipocytes and that nicotine had a more pronounced effect on ROS production, Ampk activation, and Mkp1 expression in these cells compared to those from other tissues (Fig. 6h,i) .
Next we assessed whether other activators of Ampkα2 alter Mkp1 expression and lipolysis in cultured adipocytes. We found that clinically relevant concentrations of metformin (2-20 µM), a front-line medication for the treatment of type 2 diabetes mellitus, had marginal effects in adipocytes on MKP1 expression compared to the strong effects that nicotine had on lowering MKP1 levels ( Supplementary  Fig. 7b ). However, high concentrations of metformin (2 mM) resulted in markedly greater pAMPK levels, lower MKP1 levels, and promotion of lipolysis (Supplementary Fig. 7b) . Additionally, ROS scavengers or inhibition of ROS production abolished nicotine-induced AMPK activation (Supplementary Fig. 7c) , indicating that nicotine activates AMPKα2 through ROS induction.
Nicotine-induced lipolysis and IR occurs in smokers and rats
We next investigated whether nicotine activated AMPK-MKP1-IRS1 signaling in the adipose tissues of smokers, and found higher pAMPK and lower MKP1 and IRS1 in WAT from smokers compared to that from nonsmokers (Fig. 6i) . Moreover, the blood glucose and plasma insulin response during an oral glucose tolerance test (OGTT) was significantly higher in smokers than nonsmokers (Fig. 6j) . Additionally, smokers showed lower fat percentage, higher serum FFA levels, and a higher degree of lipolysis than were observed in nonsmokers (Supplementary Fig. 7d-f and Supplementary Table 1) .
There is evidence that that low dosages of nicotine (1.5 mg kg −1 day −1 ) induce lipolysis and hepatic steatosis in mice 46 . In contrast, others report that in rats, high dosages of nicotine (3-4 mg kg −1 day −1 , equal to 6-8 mg kg −1 day −1 in mice) alleviate IR via severe weight loss, negative energy balance, increased locomotor activity, and elevated BAT thermogenesis 21, 47, 48 . To address the discrepancy between mice and rats, we investigated the metabolic effects of low dosages (0.8 mg kg −1 day −1 , equal to 1.5 mg kg −1 day −1 in mice) and high dosages (4 mg kg −1 day −1 ) of nicotine in rats. As shown in Supplementary Figure 8a -c, the low dosage of nicotine (similar to the clinical concentration within smokers) induced both IR and mild loss of body weight, whereas the high dosage of nicotine induced severe loss of body weight with improved glucose tolerance in rats.
DISCUSSION
This study has shown, for what we believe is the first time, that AMPKα2, but not AMPKα1, is essential for nicotine-induced IR and aberrant lipolysis in the WAT of mice in vivo. Mechanistically, we have demonstrated that nicotine, via elevation of ROS levels, selectively activates adipose AMPKα2, which phosphorylates MKP1 at Ser334, leading to the ubiquitination-mediated degradation of MKP1. MKP1 reduction consequently results in aberrant p38-JNK activation, which mediates IRS1 phosphorylation at Ser307, inducing its degradation, and the subsequent inhibition of AKT phosphorylation at Ser473. As a result, nicotine impairs insulin signaling in WAT, upregulates lipolysis, and elevates circulating FFA levels. This increase in circulating FFAs, in turn, impairs insulin sensitivity in other insulin-sensitive tissues, such as skeletal muscle and liver (Supplementary Fig. 8d ). Of note, nicotine considerably increases the levels of hepatic and serum triglycerides and circulating FFAs and promotes liver steatosis, all of which are ablated by lipolysis inhibition with acipimox. These results indicate that nicotine promotes lipid redistribution from fats into other organs and circulating blood, which contributes to the development of insulin resistance.
npg Although AMPK-induced activation of the p38-JNK pathway has been reported in different cell types 17, 18, 49 , the mechanism for this regulation was unclear. Here we have demonstrated that AMPKdependent MKP1 degradation is required for activation of the p38-JNK pathway. We showed that MKP1 is phosphorylated by AMPK at Ser334 and that this phosphorylation results in its ubiquitination-dependent degradation. Indeed, MKP1 has previously been reported to be susceptible to ubiquitination and degradation 50 . Dusp1 −/− mice display low body weight, less WAT, small adipocyte size, enhanced p38-Jnk activation, delayed insulin-induced pAkt in adipocytes, and elevated glucose during IPGTTs 43 , all of which are similarly seen in nicotine-treated mice. Intriguingly, AMPK can phosphorylate different proteins to exert broad functions in multiple cell types. For example, AP-2α is phosphorylated by Ampk at Ser212 in smooth muscle cells, resulting in the aberrant expression of matrix metalloproteinase 20 .
Several studies indicate that AMPK activation induces weight loss. First, AMPK activation is reported to inhibit insulin-mediated, anti-lipolysis-required IRS1-AKT signaling 31, 51 . Second, Prkaa1 −/− mice exhibit low body weight and smaller adipocyte cell size 34 , which may be due to the compensatory effects of Ampkα2 overactivation. Third, high-fat-diet-treated Prkaa2 −/− mice exhibit increased body weight, WAT mass, and adipocyte size 52 indicating an Ampkα2-dependent effect on lipolysis in adipose tissues. Finally, nicotine-activated Ampk induces lipolysis and blocks fatty acid synthase in 3T3-L1 adipocytes 19 . These effects of AMPK appear to be independent of the activation of SIRT1 and PGC-1α, two known targets of AMPK in IR 17, 18 .
Insulin is known to block lipolysis, increase body weight 53, 54 , activate IRS1-AKT signaling, and inhibit AMPK signaling 31 . Another important implication of the present study is that IR in adipocytes (that is, the suppression of insulin-induced inhibition of lipolysis) is required for whole-body IR and adiposity reduction in cigarette smokers and individuals undergoing nicotine replacement therapy. This notion is supported by the observation that nicotine has little effect on IR or adiposity reduction in Prkaa2 ∆ad mice. Furthermore, in adipocytes, nicotine suppresses the insulin-dependent blockade of lipolysis, but it does not affect basal lipolysis. Importantly, inhibition of lipolysis normalizes insulin sensitivity in skeletal muscle but not adipose tissues, suggesting that IR in skeletal muscle results from the elevation of circulating FFAs that occurs with nicotine treatment. Moreover, antilipolytic drugs such as acipimox might be beneficial for treating IR in cigarette smokers or individuals undergoing nicotine replacement therapy. Finally, we have found that nicotine preferentially targets Ampk in WAT compared to other tissues. This preference likely results from the relatively high expression of the nicotine receptor, AchRα7, in WAT compared to other tissue types and the high lipophilicity of nicotine, which would lead to its accumulation in adipose tissue 55 .
In summary, the data here show that AMPKα2 is essential for nicotineinduced lipolysis and whole-body IR. Our results might help explain the paradoxical links of weight loss and whole-body IR in cigarette smokers. Additionally, the results also suggest that anti-lipolytic drugs such as acipimox might be useful for treating IR in smokers or individuals undergoing nicotine-based smoking cessation therapy.
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